In Vitro Toxicology Testing Market to Touch a Value of Around US$ 7,750 Million by 2022


In vitro toxicity testing is the scientific examination of the outcomes of toxic chemical substances on mammalian cells or cultured bacteria. In vitro factually meant as in glass testing process are employed mainly to identify the probable hazardous chemicals in addition to confirm the requirement for certain toxic properties in the premature stages of the growth of potentially helpful new substances such as food additives, therapeutic drugs and agricultural chemicals.

The worldwide in vitro toxicology testing market is anticipated for a significant growth because of an increase in various R&D activities where in vitro testing is requisite. Additionally, the prohibition on animal testing has also led to the growing adoption of in vitro toxicology testing. The worldwide markets for in vitro toxicology testing is poised to reach a figure of close to US$ 7750 Million by 2022 and are projected for a robust CAGR throughout the estimated period.

The worldwide vitro toxicology testing market is segmented in terms of products & services, method, industry, technology and region.

Based on product & services, the overall market is further categorized into assays, services and reagents & labware. The services segment is likely to witness a robust CAGR throughout 2017-2022 and poised to reach a valuation of close US$ 2400 Million by 2022.

Based on the method type, the market for vitro toxicology testing is divided into cellular assays, biochemical assays and ex vivo models. The cellular assays division is slated to reach a market value of nearly US$ 3700 Million by 2022 exhibiting an over 5% CAGR over the projection period from 2017-2022.

Based on the industry type, the market is categorized into pharmaceutical and biopharmaceutical industry, cosmetics and household products industry, food industry and chemical industry. The pharmaceutical and biopharmaceutical industry will be gaining maximum market shares by 2022 and are estimated to reach a figure of approximately US$ 3500 Million by the end of the forecast period.

The technology segment consists of mainly cell culture technologies, high-throughput technologies, cellular imaging technologies and toxicogenomics. The cell culture technologies are expected to register a CAGR of 5% during 2017-2022.

The global market is studied across six key regions namely North America, Latin America, Europe, Japan, Asia Pacific excluding Japan and Middle East and Africa. The North American market is expected to lead the overall market among other regions in terms of valuation and is projected for a robust CAGR during the estimation period.

Request and Download Sample Report

Leave a Reply